BIIB
Price
$145.37
Change
-$0.86 (-0.59%)
Updated
Jan 31, 10:30 AM (EDT)
Capitalization
31.34B
12 days until earnings call
DSNKY
Price
$28.65
Change
+$0.54 (+1.92%)
Updated
Jan 30 closing price
Capitalization
59.21B
Ad is loading...

BIIB vs DSNKY

Header iconBIIB vs DSNKY Comparison
Open Charts BIIB vs DSNKYBanner chart's image
Biogen
Price$145.37
Change-$0.86 (-0.59%)
Volume$7.65K
Capitalization31.34B
Daiichi Sankyo
Price$28.65
Change+$0.54 (+1.92%)
Volume$246.77K
Capitalization59.21B
BIIB vs DSNKY Comparison Chart
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DSNKY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. DSNKY commentary
Jan 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongBuy and DSNKY is a Buy.

Ad is loading...
COMPARISON
Comparison
Jan 31, 2025
Stock price -- (BIIB: $146.23 vs. DSNKY: $28.65)
Brand notoriety: BIIB: Notable vs. DSNKY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 78% vs. DSNKY: 131%
Market capitalization -- BIIB: $31.34B vs. DSNKY: $59.21B
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. DSNKY’s [@Pharmaceuticals: Major] market capitalization is $59.21B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileDSNKY’s FA Score has 2 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • DSNKY’s FA Score: 2 green, 3 red.
According to our system of comparison, DSNKY is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 6 TA indicator(s) are bullish while DSNKY’s TA Score has 4 bullish TA indicator(s).

  • BIIB’s TA Score: 6 bullish, 2 bearish.
  • DSNKY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than DSNKY.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +1.78% price change this week, while DSNKY (@Pharmaceuticals: Major) price change was +0.74% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.50%. For the same industry, the average monthly price growth was +2.33%, and the average quarterly price growth was -8.43%.

Reported Earning Dates

BIIB is expected to report earnings on Apr 23, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.50% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DSNKY($59.2B) has a higher market cap than BIIB($31.3B). DSNKY has higher P/E ratio than BIIB: DSNKY (75.76) vs BIIB (26.95). DSNKY YTD gains are higher at: 4.984 vs. BIIB (-4.375). DSNKY has higher annual earnings (EBITDA): 203B vs. BIIB (2.04B). DSNKY has more cash in the bank: 825B vs. BIIB (1.05B). BIIB has less debt than DSNKY: BIIB (7.34B) vs DSNKY (143B). DSNKY has higher revenues than BIIB: DSNKY (1.28T) vs BIIB (9.84B).
BIIBDSNKYBIIB / DSNKY
Capitalization31.3B59.2B53%
EBITDA2.04B203B1%
Gain YTD-4.3754.984-88%
P/E Ratio26.9575.7636%
Revenue9.84B1.28T1%
Total Cash1.05B825B0%
Total Debt7.34B143B5%
FUNDAMENTALS RATINGS
BIIB vs DSNKY: Fundamental Ratings
BIIB
DSNKY
OUTLOOK RATING
1..100
1223
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
33
Fair valued
PROFIT vs RISK RATING
1..100
10061
SMR RATING
1..100
672
PRICE GROWTH RATING
1..100
6462
P/E GROWTH RATING
1..100
9688
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DSNKY's Valuation (33) in the null industry is somewhat better than the same rating for BIIB (78) in the Biotechnology industry. This means that DSNKY’s stock grew somewhat faster than BIIB’s over the last 12 months.

DSNKY's Profit vs Risk Rating (61) in the null industry is somewhat better than the same rating for BIIB (100) in the Biotechnology industry. This means that DSNKY’s stock grew somewhat faster than BIIB’s over the last 12 months.

DSNKY's SMR Rating (2) in the null industry is somewhat better than the same rating for BIIB (67) in the Biotechnology industry. This means that DSNKY’s stock grew somewhat faster than BIIB’s over the last 12 months.

DSNKY's Price Growth Rating (62) in the null industry is in the same range as BIIB (64) in the Biotechnology industry. This means that DSNKY’s stock grew similarly to BIIB’s over the last 12 months.

DSNKY's P/E Growth Rating (88) in the null industry is in the same range as BIIB (96) in the Biotechnology industry. This means that DSNKY’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBDSNKY
RSI
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
62%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
63%
Bullish Trend 3 days ago
75%
MACD
ODDS (%)
Bullish Trend 3 days ago
52%
Bullish Trend 3 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
53%
Bearish Trend 3 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
69%
Bullish Trend 3 days ago
70%
Advances
ODDS (%)
Bullish Trend 5 days ago
53%
Bullish Trend 4 days ago
71%
Declines
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 8 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
53%
Bearish Trend 3 days ago
74%
Aroon
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 3 days ago
76%
View a ticker or compare two or three
Ad is loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DSNKY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEVIX22.250.15
+0.68%
First Eagle US Value I
RIOIX8.49N/A
N/A
RBC International Opportunities I
FSRAX8.51N/A
N/A
Fidelity Advisor Strategic Real Ret A
FTIWX13.71N/A
N/A
Fidelity Advisor Asset Manager 20% I
DFMAX35.36N/A
N/A
Davidson Multi-Cap Equity A

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+1.26%
AMGN - BIIB
37%
Loosely correlated
+0.83%
OGN - BIIB
33%
Poorly correlated
+0.82%
NVS - BIIB
32%
Poorly correlated
+1.77%
PFE - BIIB
30%
Poorly correlated
+1.09%
GILD - BIIB
28%
Poorly correlated
+1.42%
More

DSNKY and

Correlation & Price change

A.I.dvisor indicates that over the last year, DSNKY has been loosely correlated with CHGCY. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if DSNKY jumps, then CHGCY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DSNKY
1D Price
Change %
DSNKY100%
+1.92%
CHGCY - DSNKY
38%
Loosely correlated
+9.99%
OTSKY - DSNKY
37%
Loosely correlated
-0.08%
DSKYF - DSNKY
34%
Loosely correlated
+2.68%
BIIB - DSNKY
23%
Poorly correlated
+1.26%
ALPMY - DSNKY
21%
Poorly correlated
+1.12%
More